Table 1 Baseline characteristics

Age (years)^†

56 (19-82)

Sex

Male

265 (74.9%)

Etiology of chronic liver disease

Hepatitis B virus

337 (95.2%)

Hepatitis C virus

13 (3.7%)

Tumor size

Non-B, non-C

< 5 cm

4 (1.1%)

261 (73.7%)

≥ 5 cm

93 (26.2%)

Tumor number

1

216 (61.0%)

2-3

57 (16.1%)

> 3

81 (22.8%)

Treatment modality

TACE

204 (57.6%)

PEIT

74 (20.9%)

RFA

42 (11.9%)

Surgery

34 (9.6%)

BCLC Tumor stage

A: Early

224 (63.1%)

B: Intermediate

48 (13.5%)

C: advanced

67 (18.9%)

D: end-stage

15 (4.2%)

AJCC Tumor stage

I

170 (48.0%)

II

86 (24.6%)

III

98 (27.4%)

Portal vein thrombosis

Present

65 (18.4%)

Child-Pugh class

A

247 (69.8%)

B

92 (26.0%)

C

15 (4.2%)

Serum AFP

52.0 (2.2-3, 560, 000)

(ng/mL)

< 400

244 (68.9%)

≥ 400

110 (31.1%)

Serum PIVKA-II

54.0 (2.0-42, 780)

(mAU/mL)

< 300

255 (72.0%)

≥ 300

99 (28.0%)

Laboratory parameters

Platelet count (10³/μL)^†

121 (18-610)

PT (%)^†

83 (36-126)

AST (IU/L)^†

50 (17-2036)

ALT (IU/L)^†

43 (6-1775)

Albumin (g/dL)^†

3.7 (2.1-5.0)

Total bilirubin (mg/dL)^†

1.0 (0.3-31.8)